Normalization of the IGF-IGFBP axis by sustained nightly insulinization in type 1 diabetes

Diabetes Care

Volumn 30, Issue 6, 2007, Pages 1357-1363

  Ekström, Klas ^a   Salemyr, Jenny ^a   Zachrisson, Ingmar ^a   Carlsson Skwirut, Christine ^a   Örtqvist, Eva ^a   Bang, Peter ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; GROWTH HORMONE RECEPTOR; HEMOGLOBIN A1C; INSULIN ASPART; INSULIN GLARGINE; INSULIN LISPRO; ISOPHANE INSULIN; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN C;

ADOLESCENT; ARTICLE; CLINICAL TRIAL; CORRELATION ANALYSIS; DRUG MECHANISM; FEMALE; GROWTH HORMONE RELEASE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MOLECULAR MECHANICS; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; SCHOOL CHILD; SCORING SYSTEM;

ADOLESCENT; DIABETES MELLITUS, TYPE 1; DRUG ADMINISTRATION SCHEDULE; HUMAN GROWTH HORMONE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN, ISOPHANE; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INSULIN-LIKE GROWTH FACTOR I; PUBERTY;

EID: 34249915289     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/dc06-2328     Document Type: Article

References (44)

1. Dunger DB, Acerini CL: IGF-I and diabetes in adolescence. Diabete Metab 24:101-107, 1998
2. Bajaj M, Suraamornkul S, Romanelli A, Cline GW, Mandarino LJ, Shulman GI, DeFronzo RA: Effect of a sustained reduction in plasma free fatty acid concentration on intramuscular long-chain fatty Acyl-CoAs and insulin action in type 2 diabetic patients. Diabetes 54:3148-3153, 2005
3. Ueki K, Kondo T, Kahn CR: Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms. Mol Cell Biol 24:5434-5446, 2004
4. Dominici FP, Argentino DP, Munoz MC, Miquet JG, Sotelo AI, Turyn D: Influence of the crosstalk between GH and insulin signalling on the modulation of insulin sensitivity. Growth Horm IGF Res 15:324-336, 2005
5. Moran A, Jacobs DR, Jr, Steinberger J, Cohen P, Hong CP, Prineas R, Sinaiko AR: Association between the insulin resistance of puberty and the insulin-like growth factor-I/GH axis. J Clin Endocrinol Metab 87:4817-4820, 2002
6. Dohm GL, Elton CW, Raju MS, Mooney ND, DiMarchi R, Pories WJ, Flickinger EG, Atkinson SM Jr, Caro JF: IGF-I-stimulated glucose transport in human skeletal muscle and IGF-I resistance in obesity and NIDDM. Diabetes 39:1028-1032, 1990
7. Hussain MA, Schmitz O, Mengel A, Keller A, Christiansen JS, Zapf J, Froesch ER: Insulin-like growth factor I stimulates lipid oxidation, reduces protein oxidation, and enhances insulin sensitivity in humans. J Clin Invest 92:2249-2256, 1993
8. Simpson HL, Jackson NC, Shojaee-Moradie F, Jones RH, Russell-Jones DL, Sonksen PH, Dunger DB, Umpleby AM: Insulin-like growth factor I has a direct effect on glucose and protein metabolism, but no effect on lipid metabolism in type 1 diabetes. J Clin Endocrinol Metab 89:425-432, 2004
9. Yakar S, Setser J, Zhao H, Stannard B, Haluzik M, Glatt V, Bouxsein ML, Kopchick JJ, LeRoith D: Inhibition of GH action improves insulin sensitivity in liver IGF-1-deficient mice. J Clin Invest 113:96-105, 2004
10. Edge JA, Hourd P, Edwards R, Dunger DB: Urinary GH during puberty in normal and diabetic children. Clin Endocrinol (Oxf) 30:413-420, 1989
11. Edge JA, Matthews DR, Dunger DB: The dawn phenomenon is related to overnight GH release in adolescent diabetics. Clin Endocrinol (Oxf) 33:729-737, 1990
12. Zachrisson I, Brismar K, Hall K, Wallensteen M, Dahlqvist G: Determinants of growth in diabetic pubertal subjects. Diabetes Care 20:1261-1265, 1997
13. Saukkonen T, Amin R, Williams RM, Fox C, Yuen KC, White MA, Umpleby AM, Acerini CL, Dunger DB: Dose-dependent effects of recombinant human insulin-like growth factor (IGF)-I/IGF binding protein-3 complex on overnight GH secretion and insulin sensitivity in type 1 diabetes. J Clin Endocrinol Metab 89:4634-4641, 2004
14. Daughaday WH, Phillips LS, Mueller MC: The effects of insulin and GH on the release of somatomedin by the isolated rat liver. Endocrinology 98:1214-1219, 1976
15. Bereket A, Lang CH, Blethen SL, Gelato MC, Fan J, Frost RA, Wilson TA: Effect of insulin on the insulin-like growth factor system in children with new-onset insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 80:1312-1317, 1995
16. Shishko PI, Dreval AV, Abugova IA, Zajarny IU, Goncharov VC: Insulin-like growth factors and binding proteins in patients with recent-onset type 1 (insulin-dependent) diabetes mellitus: influence of diabetes control and intraportal insulin infusion. Diabetes Res Clin Pract 25:1-12, 1994
17. Hanaire-Broutin H, Sallerin-Caute B, Poncet MF, Tauber M, Bastide R, Chale JJ, Rosenfeld R, Tauber JP: Effect of intraperitoneal insulin delivery on GH binding protein, insulin-like growth factor (IGF)-I, and IGF-binding protein-3 in IDDM. Diabetologia 39:1498-1504, 1996
18. Menon RK, Arslanian S, May B, Cutfield WS, Sperling MA: Diminished GH-binding protein in children with insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 74:934-938, 1992
19. Cheetham TD, Clayton KL, Taylor AM, Holly J, Matthews DR, Dunger DB: The effects of recombinant human insulin-like growth factor I on GH secretion in adolescents with insulin dependent diabetes mellitus. Clin Endocrinol (Oxf) 40:515-522, 1994
20. Cheetham TD, Holly JM, Clayton K, Cwyfan-Hughes S, Dunger DB: The effects of repeated daily recombinant human insulin-like growth factor I administration in adolescents with type 1 diabetes. Diabet Med 12:885-892, 1995
21. Thrailkill K, Quattrin T, Baker L, Litton J, Dwigun K, Rearson M, Poppenheimer M, Kotlovker D, Giltinan D, Gesundheit N, Martha P Jr: Dual hormonal replacement therapy with insulin and recombinant human insulin-like growth factor (IGF)-I in insulin-dependent diabetes mellitus: effects on the GH/IGF/IGF-binding protein system. J Clin Endocrinol Metab 82:1181-1187, 1997
22. Guler HP, Zapf J, Froesch ER: Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults. N Engl J Med 317:137-140, 1987
23. Brismar K, Fernqvist-Forbes E, Wahren J, Hall K: Effect of insulin on the hepatic production of insulin-like growth factor-binding protein-1 (IGFBP-1), IGFBP-3, and IGF-I in insulin-dependent diabetes. J Clin Endocrinol Metab 79:872-878, 1994
24. Bang P, Nygren J, Carlsson-Skwirut C, Thorell A, Ljungqvist O: Postoperative induction of insulin-like growth factor binding protein-3 proteolytic activity: relation to insulin and insulin sensitivity. J Clin Endocrinol Metab 83:2509-2515, 1998
25. Blat C, Villaudy J, Binoux M: In vivo proteolysis of serum insulin-like growth factor (IGF) binding protein-3 results in increased availability of IGF to target cells. J Clin Invest 93:2286-2290, 1994
26. Zachrisson I, Brismar K, Carlsson-Skwirut C, Dahlquist G, Wallensteen M, Bang P: Increased 24 h mean insulin-like growth factor binding protein-3 proteolytic activity in pubertal type 1 diabetic boys. Growth Horm IGF Res 10:324 -331, 2000
27. Heise T, Nosek L, Ronn BB, Endahl L, Heinemann L, Kapitza C, Draeger E: Lower within-subject variability of insulin detemir in comparison to NPH insulin and glargine in people with type 1 diabetes. Diabetes 53:1614-1620, 2004
28. Porcellati F, Rossetti P, Pampanelli S, Fanelli CG, Torlone E, Scionti L, Perriello G, Bolli GB: Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with type 1 diabetes mellitus given meal-time lispro insulin. Diabet Med 21:1213-1220, 2004
29. Thisted H, Johnsen SP, Rungby J: An update on the long-acting insulin analog glargine. Basic & Clin Pharmacol Toxicol 99:1-11, 2006
30. Murphy NP, Keane SM, Ong KK, Ford-Adams M, Edge JA, Acerini CL, Dunger DB: Randomized cross-over trial of insulin glargine plus lispro or NPH insulin plus regular human insulin in adolescents with type 1 diabetes on intensive insulin regimens. Diabetes Care 26:799-804, 2003
31. Tanner JM, Whitehouse RH: Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty. Arch Dis Child 51:170-179, 1976
32. Bang P, Eriksson U, Sara V, Wivall IL, Hall K: Comparison of acid ethanol extraction and acid gel filtration prior to IGF-I and IGF-II radioimmunoassays: improvement of determinations in acid ethanol extracts by the use of truncated IGF-I as radio ligand. Acta Endocrinol (Copenh) 124:620-629, 1991
33. Juul A, Bang P, Hertel NT, Main K, Dalgaard P, Jorgensen K, Muller J, Hall K, Skakkebaek NE: Serum insulin-like growth factor-I in 1030 healthy children, adolescents, and adults: relation to age, sex, stage of puberty, testicular size, and body mass index. J Clin Endocrinol Metab 78:744-752, 1994
34. Pihl S, Carlsson-Skwirut C, Berg U, Ekstrom K, Bang P: Acute Interleukin-6 infusion increases IGFBP-1 but has no short-term effect on IGFBP-3 proteolysis in healthy men. Horm Res 65:177-184, 2006
35. Westwood M, Gibson JM, Davies AJ, Young RJ, White A: The phosphorylation pattern of insulin-like growth factor-binding protein-1 in normal plasma is different from that in amniotic fluid and changes during pregnancy. J Clin Endocrinol Metab 79:1735-1741, 1994
36. Burdick J, Chase HP, Slover RH, Knievel K, Scrimgeour L, Maniatis AK, Klingensmith GJ: Missed insulin meal boluses and elevated hemoglobin A1c levels in children. Pediatrics 113:221-224, 2004
37. Taylor AM, Dunger DB, Preece MA, Holly JM, Smith CP, Wass JA, Patel S, Tate VE: The GH independent insulin-like growth factor-I binding protein BP-28 is associated with serum insulin-like growth factor-I inhibitory bioactivity in adolescent insulin-dependent diabetics. Clin Endocrinol (Oxf) 32:229-239, 1990
38. Juul A, Moller S, Mosfeldt-Laursen E, Rasmussen MH, Scheike T, Pedersen SA, Kastrup KW, Yu H, Mistry J, Rasmussen S, Muller J, Henriksen J, Skakkebaek NE: The acid-labile subunit of human ternary insulin-like growth factor binding protein complex in serum: hepatosplanchnic release, diurnal variation, circulating concentrations in healthy subjects, and diagnostic use in patients with GH deficiency. J Clin Endocrinol Metab 83:4408-4415, 1998
39. Saukkonen T, Shojaee-Moradie F, Williams RM, Amin R, Yuen KC, Watts A, Acerini CL, Umpleby AM, Dunger DB: Effects of recombinant human IGF-I/IGF-binding protein-3 complex on glucose and glycerol metabolism in type 1 diabetes. Diabetes 55:2365-2370, 2006
40. Bang P, Ahlsen M, Berg U, Carlsson-Skwirut C: Free insulin-like growth factor I: are we hunting a ghost? Horm Res 55 (Suppl 2):84-93, 2001
41. Berg U, Gustafsson T, Sundberg CJ, Carlsson-Skwirut C, Hall K, Jakeman P, Bang P: Local changes in the insulin-like growth factor system in human skeletal muscle assessed by microdialysis and arteriovenous differences technique. Growth Horm IGF Res 16:217-223, 2006
42. Nichols TC, du Laney T, Zheng B, Bellinger DA, Nickols GA, Engleman W, Clemmons DR: Reduction in atherosclerotic lesion size in pigs by alphaVbeta3 inhibitors is associated with inhibition of insulin-like growth factor-I-mediated signaling. Circ Res 85:1040-1045, 1999
43. Schrijvers BF, De Vriese AS, Flyvbjerg A: From hyperglycemia to diabetic kidney disease: the role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines. Endocr Rev 25:971-1010, 2004
44. Rachmiel M, Perlman K, Daneman D: Insulin analogs in children and teens with type 1 diabetes: advantages and caveats. Pediatr Clin North Am 52:1651-1675, 2005